PT-141 benefits include increased sexual desire in some premenopausal women, but the peptide is not approved for men or for general wellness use.
PT-141 (bremelanotide) can increase sexual desire in some premenopausal women who have hypoactive sexual desire disorder, or HSDD. The FDA approved it in 2019 under the brand name Vyleesi as a subcutaneous autoinjector, and it is not approved for men, for postmenopausal women, or for general wellness or tanning use. The benefits are real but narrow: PT-141 targets low desire, not relationship strain, fatigue, or hormonal imbalances.
What PT-141 Actually Is
PT-141 is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. It acts as a melanocortin receptor agonist, and most researchers credit its effect on desire to activation of MC4 receptors in the brain.
That mechanism is what separates it from erectile dysfunction drugs. PT-141 does not work by increasing blood flow to the genitals; it works on the central nervous system, which is why clinicians describe it as a desire drug rather than a performance drug.
Bremelanotide is the generic name and Vyleesi is the brand name. In the United States, the peptide is legally available only by prescription.
The Main PT-141 Benefits Reported in Research
Most summaries of pt-141 peptide benefits focus on desire and distress scores from the phase 3 RECONNECT trials. In those trials, women with HSDD who used bremelanotide reported higher desire and less bother from low desire than women who received a placebo.
It is just as important to know what PT-141 does not do. PT-141 is not an approved treatment for erectile dysfunction, it does not raise testosterone, and it does not fix the medication side effects, mood disorders, or relationship problems that frequently drive low libido.
| Reported benefit | Strength of evidence | What to know |
|---|---|---|
| Increased sexual desire in premenopausal women | FDA-approved indication for HSDD | Average improvement is modest; not everyone responds |
| Less distress about low desire | Supported by phase 3 trial data | Measured alongside desire scores |
| On-demand dosing instead of daily pills | Approved label | Injected at least 45 minutes before activity |
| Improved erectile function in men | Early-stage and off-label | Small studies, sometimes combined with PDE5 inhibitors |
| Skin darkening (tanning effect) | Known side effect, not a benefit | A melanocortin class effect, not a reason to use the drug |
PT-141 Benefits for Women
The FDA approval covers premenopausal women with acquired, generalized HSDD. "Acquired" means low desire developed after a period of normal desire, and "generalized" means it shows up in most situations rather than with only one partner.
Women outside that definition are not covered by the approval. That includes postmenopausal women, women whose low desire is situational, and women whose low desire stems from another medical condition or from a medication.
Any discussion of pt-141 benefits for woman should start with the trial numbers, because they set realistic expectations. In the two phase 3 RECONNECT trials, roughly one in four women on bremelanotide met the threshold for a meaningful improvement in desire, compared with about one in six on placebo.
How Long Does PT-141 Last?
PT-141 is an on-demand drug, not a daily one. The approved label directs users to inject at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month.
Blood levels peak about an hour after injection, and the half-life is roughly 2.7 hours. Most people notice the strongest effect within the first few hours, though some report a difference that lingers longer.
If you want to know how long does pt-141 last in your own case, track timing and response over several doses with your prescriber. Response varies widely between individuals, and the drug does not work for everyone who tries it.
PT-141 Nasal Spray vs. the Approved Injection
The only FDA-approved version of PT-141 is a subcutaneous autoinjector that delivers 1.75 mg. Bremelanotide was originally studied as a nasal spray, but that formulation was dropped during development because of blood pressure increases and inconsistent absorption.
Nasal sprays sold online as research chemicals are not FDA approved, are not verified by an independent lab, and may contain a different amount of peptide than the label claims. A pt-141 nasal spray purchased from a gray-market vendor carries risks that the prescription product does not.
| Feature | Vyleesi (approved injection) | Gray-market nasal spray |
|---|---|---|
| FDA approval | Yes, for premenopausal HSDD | No |
| Dose control | Fixed 1.75 mg autoinjector | Unknown and variable |
| Quality and sterility testing | Required by regulators | Not verified |
| Blood pressure guidance | Labeled warnings and contraindications | None provided |
Side Effects and Safety Considerations
Nausea is the most common side effect and affected roughly 40 percent of participants in clinical trials. Flushing, headache, vomiting, and injection site reactions are also frequently reported.
PT-141 can raise blood pressure temporarily. People with uncontrolled high blood pressure or known cardiovascular disease should not use bremelanotide.
Darkening of the skin, gums, and parts of the face has been reported, particularly with frequent dosing. This hyperpigmentation is a known class effect of melanocortin agonists rather than a rare anomaly.
Talk with a healthcare professional before using PT-141, especially if you take blood pressure medication, antidepressants, or hormonal contraceptives. This article is informational and is not a substitute for medical advice.
Legal Status and Where to Buy PT-141
PT-141 requires a prescription in the United States and is dispensed through certified specialty pharmacies. The manufacturer ships the autoinjector directly to patients after a clinician evaluates them.
If you are searching for where to buy pt-141, the legitimate route is a licensed clinician who can confirm whether you meet the criteria for HSDD and write a prescription. Websites that market it as a research chemical or a generic peptide without a prescription are selling an unapproved product.
Dose limits matter more than dose increases. One dose per 24 hours and no more than eight doses per month is the labeled maximum, and no evidence suggests that taking more improves results.
The Bottom Line on PT-141
PT-141 offers a genuine, FDA-reviewed option for a specific group: premenopausal women with acquired, generalized HSDD. For everyone else, the evidence is thinner, the product is off-label, and the risks do not disappear.
PT-141 is not FDA-approved for men or for postmenopausal women. Anyone considering bremelanotide should weigh modest average benefits against nausea, blood pressure changes, and hyperpigmentation, and should make that decision with a clinician rather than an online vendor.
Frequently Asked Questions
Does PT-141 work for men?
PT-141 is not FDA-approved for men. A few small studies have looked at bremelanotide for erectile dysfunction, sometimes alongside PDE5 inhibitors like sildenafil, and reported some improvement, but the evidence is limited and no regulator has cleared it for that use.
How quickly does PT-141 start working?
The approved label says to inject at least 45 minutes before anticipated sexual activity. Blood levels peak around one hour after dosing, and the half-life is roughly 2.7 hours, so most users notice effects within a few hours.
Are PT-141 nasal sprays sold online safe?
Nasal sprays marketed as research chemicals are not FDA-approved, are not tested for sterility or accurate dosing, and may not contain the amount of peptide listed on the label. The only approved form of PT-141 is a 1.75 mg prescription autoinjector.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.